title: Sunitinib malate.
abstract: Recently, there has been a growing interest in understanding the role of receptor tyrosine kinases (RTK), such as vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), stem cell factor receptor (KIT), and fms-like tyrosine kinase 3 (FLT3), in promoting tumor angiogenesis, tumor growth and metastasis. Sunitinib (sunitinib malate; SU11248; SUTENT; Pfizer Inc, New York, NY, USA) is a novel, orally bio-available, oxindole, multi-targeted tyrosine kinase inhibitor with high binding affinity for VEGFR and PDGFR which has shown anti-tumor and anti-angiogenic activities. This drug recently received approval from the US Food and Administration (FDA) in two indications simultaneously: advanced renal cell carcinoma (adRCC) and gastrointestinal stromal tumors (GIST), in patients who are resistant or intolerant to the treatment with imatinib. The present article reviews the recent pharmacologic and clinical data related to the use of this new promising drug in the field of oncology.
authors.affiliation: Department of Nephrology, Pitie-Salpetriere Hospital 83, Blvd de l'Hôpital, 75013 Paris, France. hassan.izzedine@psl.ap-hop-paris.fr
authors.forename: Hassane
authors.initials: H
authors.lastname: Izzedine
authors.forename: Irina
authors.initials: I
authors.lastname: Buhaescu
authors.forename: Olivier
authors.initials: O
authors.lastname: Rixe
authors.forename: Gilbert
authors.initials: G
authors.lastname: Deray
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D018288:Carcinoma, Small Cell; D002455:Cell Division / Q000187:drug effects; D045744:Cell Line, Tumor; D018450:Disease Progression; D004730:Endothelium, Vascular / Q000166:cytology / Q000187:drug effects; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D046152:Gastrointestinal Stromal Tumors; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D007951:Leukemia, Myeloid; D008175:Lung Neoplasms; D011758:Pyrroles / Q000627:therapeutic use*; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D040262:Receptors, Vascular Endothelial Growth Factor / Q000037:antagonists & inhibitors; D000077210:Sunitinib
chemical_list: D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D007211:Indoles; D011758:Pyrroles; D020794:Receptor Protein-Tyrosine Kinases; D040262:Receptors, Vascular Endothelial Growth Factor; D000077210:Sunitinib